

BIOSPHERE 2022

UTAH'S LIFE SCIENCES INDUSTRY MAGAZINE

21

**INTERMOUNTAIN
INNOVATING
BEYOND
HEALTHCARE
DELIVERY**

**TRAILBLAZING
STARTUPS**

7

**BIG COMPANY
IDEAS**

30

**FORGING A
REVOLUTION
IN CANCER**

34

**CACHE VALLEY'S
LIFE SCIENCES
BOOM**

26

INNOVATION_





**GOOD
IDEAS
NEED
A
PLACE
TO
INCUBATE.**

LETTER FROM THE CHAIR

Welcome to the 2022 *Biosphere Magazine* - a BioUtah publication highlighting Utah's life sciences community. In the pages that follow, we give you a front row seat to Utah's BioHive, one of the fastest growing life sciences hubs in the nation.

This impressive distinction brings with it a surge in economic development, job creation and more than \$13 billion in state GDP. But that's not all. Our highly acclaimed bio ecosystem also powers tremendous innovation. Innovation, truly the heart and soul of our industry, drives the vital work we do to improve patients' lives each and every day.

Inside, we tell the story of companies small and large, from visionary startups to established global companies, who are pioneering advances in life-saving medical devices, diagnostics and therapies. We spotlight northern Utah's Cache Valley, which is experiencing a sizable boom in the industry. Utah's healthcare systems, such as Intermountain

Healthcare - our feature focus - play an important role as well, advancing medical breakthroughs and disrupting the status quo to reduce healthcare costs while fighting our most formidable diseases. The "buzz" in the BioHive community is catching on and investors are taking notice with more of our life sciences companies going public.

I have never been as excited about our BioHive than I am today. We are proud of how far we've come and inspired by what the future holds. Read on and join the journey!

Sincerely,



Brad Brown
Chair, Board of Directors, BioUtah,
Executive Chairman, ATL Technology



Genomic | Epigenomic | Proteomic

Bringing Clinical Science to Life

Noninvasive Saliva Testing Diagnostics-as-a-Service (DaaS)

Stabilize, Preserve, & Amplify
DNA at the Point-of-Collection

We believe when you bridge the gap between science and real medical solutions you deliver innovation with the practical power to impact and change outcomes.

spectrumsolution.com



CONTENTS



21

INNOVATING BEYOND HEALTHCARE DELIVERY

Intermountain's Cutting-Edge Initiatives to Fast-Forward Medicine and Patient Care



7

START-UP INNOVATION

These Innovators are Blazing Trails to Change the Future of Healthcare



26

CACHE VALLEY

Inside Cache Valley's Life Sciences Boom



34

FORGING A REVOLUTION IN CANCER

Taking on Cancer with Gutsy New Thinking About Early Detection and Treatments



30

BIG IDEAS

Industry Heavyweights Don't Rest on Their Laurels When it Comes to Life-Changing Medical Technologies



15

WHAT'S ALL THE BUZZ ABOUT?

Igniting a Connection Culture in the BioHive Community

12

A BOLD MOVE FOR HEALTH TECH

How U of U President Taylor Randall is Pushing the Boundaries of Science and Discovery

18

PUBLIC COMPANIES

CEOs Talk About Going from Startup to Stock Market

38

ADVOCACY

Utah Legislators Lean in on Life Sciences



A Publication by BioUtah
230 East South Temple, Suite 100
Salt Lake City, UT 84111
801-867-4061
bioutah.org

Distributed by *Utah Business.*

CONTRIBUTORS

JoAnne Alkire
Amanda Ashley
David J. Bearss
Jared Bearss
Denise Bell
Rachel Bird
Robert Bogdan
Adam Brown
Brad Brown
Brad Call
Dustin Cefalo
Sarah Comstock
Denny Crockett
Kelvyn Cullimore
Jackie Dorsky
Jessica Fossmeyer

Marcus Gerhardt
Nate Gibby
Challis Gill
Cory Grand
Andi Groen
Bretni Kennon
Keri Laden
Mark Lehmkuhle
Frank Maguire
Megan Manzari
Andrea Mazzocchi
Josel McCabe
Britt McPartland
Andrew S. Nelson
Holly Nelson
Kent Nelson

Bo Nemelka
William Niedermeyer
David Nilson
Stephen Norton
Ryan Parker
Andy Robertson
Joshua Schiffman
Jeffrey Schmidt
Katie-Rose Skelly
Thomas Slavin
Florian Solzbacher
Taryn Southern
Brent Taylor
Natalie Themm
Steve Warner
Amanda Warren

LETTER FROM UTAH'S GOVERNOR



STATE OF UTAH

SPENCER J. COX
GOVERNOR

OFFICE OF THE GOVERNOR
SALT LAKE CITY, UTAH
84114-2220

DEIDRE M. HENDERSON
LIEUTENANT GOVERNOR

Dear Reader,

Utah is one of the top states in the nation for businesses to grow and thrive, making our economy one of the strongest in the nation. A key part of our growing economy is the life sciences industry. BioUtah and the BioHive have played crucial roles in expanding life sciences innovation across the state, and their progress has been impressive.

Life sciences have become a strategic pillar of Utah's economy. The industry embodies entrepreneurship and innovation in its work to improve and save lives through advanced testing, novel technologies, and groundbreaking cures.

Utah is committed to elevating life sciences in our schools, research centers, and manufacturing facilities through targeted local and regional initiatives. These initiatives will help the life sciences industry in Utah continue to grow.

Utah is one of the best states in the nation to live, work, and raise a family. If your company is not in Utah, we encourage you to come visit the Beehive state.

Sincerely,

Spencer J. Cox
Governor of Utah

START-UP INNOVATION



The story starts, as all good stories do, with a mind-bending idea: I want to create the link between human and artificial limb.

That's the dream Florian Solzbacher shared with Marcus Gerhardt almost thirty years ago at Atlantic College.

Today, the two are co-founders of Blackrock Neurotech, a company that sprang from a University of Utah lab and is now the global leader in medical brain-computer interface (BCI) technology.

BCIs are implantable technologies that translate brain signals into commands to control external devices, like computers or prosthetics. They can also convey sensory information back to the brain, so the user can actually "sense" touch. These cutting-edge devices have thus far enabled paralyzed individuals to eat, drink, type, make art, and even control robotic arms — with just their brain signals.

Innovation in healthcare involves the ability to imagine today the breakthroughs of tomorrow.

These trailblazing Utah startups are doing just that - creating unique technologies and treatments to restore mobility, advance brain health, tackle bacterial resistance, create human-like heart valves, target inflammatory disease and transform vaccine development. Where we see extraordinary challenges, they see new frontiers and the opportunity to change lives for the better.



Blackrock Neurotech's Utah Array is a 4.2 millimeter square grid with 100 silicon electrodes.

Until now, patients could only access this technology through multimillion-dollar research studies, but that is changing—Blackrock Neurotech plans to submit its first commercial device to the FDA in 2023.

The commercialization of Blackrock Neurotech's technology will be life-changing for millions—and the realization of a lifelong dream. "As long as you can interface with the brain, you can enable a patient to regain what was lost," said Solzbacher. "It's endless, the possibilities."

Epitel's development pipeline includes an ambulatory version of REMI designed to be used for weeks of continuous monitoring outside of the hospital, enabled by machine learning support software. Automated machine learning is being developed for detection of seizures and may enable wearable EEG technology to inform users and eventually patients of daily seizure counts, of alerts to seizures in real time and of seizure event probability forecasts.



Epitel's REMI System

As a window to the brain, Epitel's long-term EEG monitoring may be a key development in unlocking the prediction of many types of neurological disorders.



Epitel is a digital health company revolutionizing brain health monitoring by combining wireless, easy-to-use, wearable EEG technology with cloud-based remote access capabilities. The company's first FDA cleared product, the REMI™ System, is a quickly deployable EEG screening platform for remote monitoring in hospital emergency rooms and critical care units.

"REMI is an everyday solution that provides a fast history of brain activity at the point-of-care," said Mark Lehmkuhle, Epitel's CEO and founder. "This allows for timely, informed clinical decisions and provides hospitals with a simple and effective solution to monitor seizure activity."





Due to the overuse of antibiotics globally, multidrug resistant bacteria are widely regarded as a significant world health threat. EVÖQ Nano's nanotechnology is fighting against these bacteria, labeled "superbugs" by the World Health Organization.



William Niedermeyer, EVÖQ Nano's Founder

Thanks to generous funding from the Cystic Fibrosis Foundation, the company is developing pulmonary antimicrobial therapeutics to tackle challenging bacterial infections common in cystic fibrosis. They're using patented high-energy manufacturing to produce an active pharmaceutical ingredient with a novel mechanism against bacterial pathogens.

The company is now engaged in IND-enabling studies and anticipating starting Phase I clinical trials in early 2024. This is welcome news for patients who acquire these harmful infections.

"With personal humility, reliability and scientific rigor, we boldly aim to engineer novel health solutions to improve lives," said Brian Bertha, president and CEO of EVÖQ Nano.

EVÖQ Nano is also leveraging the same technology to inhibit bacterial and biofilm growth in medical devices, which could dramatically reduce hospital-acquired infections and procedural complications. For the past 100 years, antibiotics have borne the weight of fighting bacterial infections. EVÖQ Nano aims to ease that burden.



Rather than seek to improve on existing technology, Foldax decided to reinvent every aspect of the heart valve – from material to design to manufacturing – creating a platform of surgical and minimally-invasive transcatheter valves. Its TRIA™ heart valve platform addresses historical tradeoffs inherent in today's commercial heart valves, including durability, patient quality of life and costly manufacturing.

All TRIA heart valve products combine their proprietary LifePolymer™ – with an innovative valve design intended to resist calcification, withstand stresses and strains without failure, and restore quality of life without lifelong patient use of blood thinning medication. In less than 10 years, Foldax has brought surgical aortic and mitral valves to the clinic with a Transcatheter Aortic Valve Replacement [TAVR] version clinically ready by year end.



Tria™ - Next-Generation Heart Valve

"In the process of making a better valve, we intend to change the face of the heart valve industry," said Foldax CEO Frank Maguire. "Foldax is democratizing the manufacturing of heart valves by eliminating the

need for centralized global manufacturing and replacing it with a small footprint robotic manufacturing pod that can be placed in any region of the world. Every day we are striving to make the highest quality valves incredibly efficient and accessible."



Halia Therapeutics aims to eliminate chronic inflammation to treat neurodegeneration and inflammatory diseases. Halia's team, led by brothers Jared and David Bearss, targets immune cell signaling and will target inflammation in diseases such as rheumatoid arthritis, macular degeneration, Alzheimer's, colitis, Parkinson's, multiple sclerosis and IBD, among others.



Halia Therapeutics is discovering and developing novel therapeutics to improve the lives of patients with inflammatory disorders and neurological diseases.

"The ability to both inhibit the assembly and promote the disassembly of the NLRP3 inflammasome complex represents a significant opportunity to provide new therapeutics for patients suffering from neurological and inflammatory diseases," said Halia's COO, Jared Bearss. Persistent activation of the NLRP3 inflammasome is thought to drive the onset and progression of many conditions.

John "Keoni" S. K. Kauwe III, co-founder and chair of the Scientific Advisory Board of Halia and an expert in the study of Alzheimer's disease, said, "Our method of targeting the NLRP3 inflammasome has a potential impact on not just Alzheimer's disease but many diseases tied to inflammation."

Dr. David J. Bearss, president and CEO of Halia Therapeutics, said, "We are excited to have advanced our drug into the clinic and look forward to exploring its potential to treat diseases driven by chronic inflammation."



Hexamer Therapeutics along with partner Innovative Vaccine Technologies (IVT) likens their development of a new, powerful and flexible vaccine platform to innovating from vacuum tubes to micro-processors.



Brad Call, IVT co-founder


The teams' genesis began in discovering a promising and patented approach to treating advanced prostate and triple negative breast cancers. This breakthrough also led to utilization of the platform for vaccines in the fight against viral pandemics, including COVID-19.

The therapeutic vaccine manufacturing and production will be 100% U.S. based with a ground-up facility planned in Utah.

Hexamer Therapeutics' technology provides many safety, production and cost benefits. The vaccines are made entirely of self-assembling amino acids which already abound within the human body.

Moreover, the platform provides a rapid response to future viral outbreaks or bioterrorism as billions of doses can be made in just months and shipped and stockpiled as a dry powder without special cold-chain considerations, thereby drastically reducing cost and ease of distribution.

"We know this patented platform technology will absolutely change the world for the better and save countless lives," said Brad Call, co-founder of IVT.

An Animal Challenge Study with Mount Sinai Icahn School of Medicine showed the company's COVID-19 vaccine to be 80% effective with only a single dose along with lengthy durability predicted to be measured in years, not months. 



bioMérieux Manufacturing, Salt Lake City, Utah

FFKR ARCHITECTS | Science and Technology Studio

FFKR Architects Science + Technology Design Studio focuses on emerging growth industries in the market sectors of science, technology, biomedical instrument manufacturing, lab space, research and development facilities, and clean room design.



bioMérieux Administration, Salt Lake City, Utah

We can directly assist with the planning, programming and expansion efforts of capital improvements for companies with highly specialized technical requirements including labs, clean room spaces, manufacturing areas, and support spaces.

Our body of work ranges from small laboratories to major new manufacturing facilities. We bring to each project a commitment to achieving the goals and aspirations of the client. We are known for our ability to collaborate with scientists, researchers, and administrators, and to facilitate consensus among project stakeholders.

The value of working with the Science + Technology Design Studio is that we assist our clients in the design of exemplary facilities that are cost-effective to construct and maintain; with flexibility for future expansion, both physically and technologically in an era of rapid change.



A BOLD MOVE FOR HEALTH TECH



The University of Utah (U) is an innovative force in health technology in the State of Utah. From the first artificial heart transplant to the discovery of myriad cancer-causing genes, researchers at the U continue to push established boundaries in the health industry. Now, university president Taylor Randall wants to push even farther, with innovation representing one of the three pillars supporting his vision of the U's future. Randall's plan focuses on two areas: boosting research and streamlining the transfer of technology to markets.

"Higher education has progressed through two major evolutions: reading, writing, and arithmetic, and then research," said Randall. "We are just beginning the third evolution—entrepreneurship. This is where we take the learning and knowledge enterprise beyond campus to improve lives and change the world."

Over the last decade, U researchers have brought in historic amounts of funding. This culminated in an unprecedented \$641 million in 2021. By expanding the footprint of basic research projects, Randall has challenged the institution to secure and sustain \$1 billion of research funding annually within seven years.




"We need to see if the pathbreaking work by Eric Garland can help solve the opioid crisis. We hope that Michelle Litchman's research on diabetes results in significant policy changes. We see Florian Solzbacher's research on the brain-computer interface implemented in Blackrock Neurotech," added Randall.

To speed the transfer of technology to relevant markets, Randall has pledged to invest \$100 million into what is dubbed "Greenhouse Research." Therapeutics,

orthopedics, diagnostics and energy are just a few examples of Greenhouses that aim to address society's urgent issues. These will likely translate into commercially viable enterprises.

The Partners for Innovation, Ventures, Outreach & Technology (PIVOT) Center leads the U's strategy and operation for technology commercialization, corporate engagement and economic development. PIVOT supports research ideas through their entire lifecycle, from the laboratory bench to the wider world. Through PIVOT's efforts, revenues from patents and licensing agreements have skyrocketed to an historic high of \$21.5 million in 2021.

"Utah's life sciences community has made incredible strides recently," said Keith Marmer, chief innovation and economic engagement officer of the U. "With our Greenhouses we look forward to supporting President Randall's vision for innovation and speeding the transition of research to the market." 



PROJECT DELIVERY, EVOLVED.

PROTECSINC.COM
(833) PRO-1900

CONSTRUCTION MANAGEMENT, DESIGN/BUILD AND INTEGRATED PROJECT DELIVERY

Specializing in: Cleanrooms, Manufacturing, Pharmaceutical, Medical Device, Specialty Chemical, Advanced Materials, Food and Beverage, Wet/Dry Labs, cGMP Warehouses, Higher Education, Life Sciences Office, Data Centers, Healthcare

SALT LAKE CITY, UT
801-441-7744 ext. 414

RALEIGH, NC PLYMOUTH MEETING, PA NEWARK, DE BRIDGEWATER, NJ



Made for today, tomorrow and for what's needed next

Anticipating your needs before they arise is how we help you stay ahead. For 125 years, BD has known one thing to be true—for healthcare professionals to be at their best, they need the best. That's why we're continually envisioning the solutions of tomorrow by innovating today.

Visit [bd.com](https://www.bd.com) to learn more.



BD

Advancing the
world of health™

WHAT'S ALL THE BUZZ ABOUT?



BioHive is a public-private nonprofit organization established in 2020 by industry and government leaders to support employees of Utah's life sciences and healthcare innovation. BioHive has been tasked with educating people about the industry, building community, facilitating volunteerism and importantly, creating a "hub" for vibrant and sustainable sector growth. This is no small task as industry studies have confirmed that Utah is a fast-growing state for life sciences growth, job creation and economic prosperity.

"We have one of the fastest growing healthcare innovation communities in the nation, backed by a huge manufacturing sector," said BioHive Executive Director, Katelin Roberts, during her address at the governor's One Utah Summit. "We need all these sectors (diagnostics, therapeutics, devices and digital health etc.) working in harmony to take care of patients. When you think of BioHive, think of the companies and people in this industry that bring hope to the hopeless—giving people time back in their lives."

BioHive tells the story of this dedicated community, which includes over 1,300 companies and 150,000 employees. The range of employment opportunities in the industry is vast, from manufacturing and logistics to discovering new medicines for diseases that have no treatments. This produces a uniquely diverse workforce with tremendous economic power and upward mobility. BioHive educates people about these opportunities by highlighting employees in industry and emphasizing women in STEM, DEI, the underrepresented populations, education and workforce development.

In addition to its storytelling and education efforts, BioHive is the hub creating opportunities for companies and employees to engage together and with their communities. In June 2022, BioHive hosted its inaugural women's event where more than 180 people gathered to connect, give back and show support for the women shaping the future of life sciences and healthcare innovation in Utah.

Notably, BioHive took the stage to announce a \$10,000 grant back to the industry in the form of creating a cross-company "BioHive women in science and technology seminar committee" which will accelerate mentorship and leadership opportunities for women in the BioHive community. The committee includes representatives from Recursion, ARUP, UHealth, BD, bioMérieux, Health Catalyst, Known Medicine and BioHive.

The evening began with a volunteer project for the Utah STEM Action Center. Following the volunteer project, attendees were treated to a panel discussion that included some of Utah's best and brightest, including: Dr. Tracy George, CEO of ARUP, Dr. Nina de Lacy from the University of Utah, Dr. Alison O'Mahony of Recursion and Tami Door of QFactor. These incredible women shared the stories that brought them to their respective positions of leadership.


In its post-event survey, BioHive received incredible feedback from attendees:

"The work of BioHive is more than a networking organization, it has tangible and constructive influence on individuals and businesses."

"There is a bigger women biotech community in Utah than I expected."

"There are more opportunities for women in science in the valley than I originally thought."

"I am not a unicorn in SLC. As a woman, immigrant-scientist there is a group of unicorns here! What a great opportunity!"

For individuals or corporations looking to make a difference, BioHive provides many opportunities to get involved and give back. 

Participants in the inaugural BioHive Women's Event assemble packets for the STEM Action Center.





Together,
we can.

Pandemics, food insecurity, climate change. These are the challenges biotechnology is striving to tackle every day. But breakthroughs just don't happen by themselves. They — like all of us — need an advocate. BIO is that advocate. We are here to help pave the way for positive change. So together, we can make breakthroughs possible — and accessible — for all.



Where
breakthroughs
begin

[bio.org](https://www.bio.org)

Utah's Public LIFE SCIENCES Companies

Utah is home to thousands of life sciences companies of all sizes. As these companies grow, they require more and more capital for completing clinical trials, commercializing product, financing expansion and the like. Many vehicles exist for raising capital, but going public is often viewed as the pinnacle.

The number of public life sciences companies in Utah is growing. In the last 18 months alone, Clene, Owlet, Recursion Pharma and Sera Prognostics have all gone public. CEO's explain why.

"At Recursion, our mission is to decode biology to radically improve lives. This is a challenging task that, in addition to innovation and good science, will require time, funding and the support of investors, public and private, who want to change the world with us. Going public allowed us to invite more individuals along on this journey."

- Chris Gibson, CEO, Recursion Pharma

"It really ties back to our mission, and the theme of our listing announcement: 'This one's for the babies'. Being a public company allows us more access to capital to build our connected nursery ecosystem, more funding in the future of infant health research and more innovation, as we remain relentless in our pursuit of better care for babies around the globe"

- Kurt Workman, CEO, Owlet

"Several factors made it appealing to take Sera public - the availability of capital, the strength of our clinical and economic data, our focus and ability to improve the health of mothers and babies, and thereby to decrease the costs of healthcare delivery - all made sense."

- Greg Critchfield, CEO, Sera Prognostics.



Company Name	Stock Exchange	Ticker Symbol	Stock Quote*
BD	NYSE	BDX	\$252.42
Clene	NASD	CLNN	\$2.96
CoDiagnosics	NASD	CODX	\$3.38
Danaher/Cytiva	NYSE	DHR	\$269.91
Denali Therapeutics	NASD	DNLI	\$27.67
Dynatronics	NASD	DYNT	\$0.61
Edwards	NYSE	EW	\$90.10
Fresenius	NYSE	FMS	\$17.10
GE Healthcare	NYSE	GE	\$73.44
Haemonetics	NYSE	HAE	\$75.03
ICU Medical	NASD	ICUI	\$159.00
Illumina/IDbyDNA	NASD	ILMN	\$201.64
Johnson & Johnson	NYSE	JNJ	\$161.34
Lipocine	NASD	LPCN	\$0.58
Merit Medical	NASD	MMSI	\$59.23
Myriad Genetics	NASD	MYGN	\$22.34
Owlet	NYSE	OWLT	\$1.62
PolarityTE [™]	NASD	PTE	\$1.02
Recursion	NASD	RXRX	\$10.51
Renalytix	NASD	RNLX	\$2.08
Sera Prognostics	NASD	SERA	\$2.10
SINTX	NASD	SINT	\$0.46
Sotera/Nelson Labs	NASD	SHC	\$16.91
Stryker	NYSE	SYK	\$205.20
Sumitomo Pharma Oncology	TSO	4506	\$7.48
TEVA Pharmaceuticals	NYSE	TEVA	\$9.04
Thermo Fisher	NYSE	TMO	\$545.32
Ultragenyx	NASD	RARE	\$47.69
Utah Medical	NASD	UTMD	\$91.90
Varex Imaging	NASD	VREX	\$21.09

* Stock price as of August 31, 2022.





CAPTIS

Geneva, London, Los Angeles, New York City, Salt Lake City, San Francisco

Life Sciences Executive Search Now Headquartered in Utah

A Word from the Founder:

It is all about people. People are the most important asset of any organization – the truest asset. People are the foundational building stone of any project, any innovation, any success. We value, we know, we understand people. Over decades, we have honed the precision-sharp skill of matching individuals' capacities and capabilities with our corporate clients' projects and environments, enabling both our clients and the placed executives to realize their maximum potential for success.

Our client base includes multinational corporations, mid-size companies, innovative start-ups, each of which values our utmost commitment to confidentiality, ethics, knowledge of the industry, and knowledge of their business. With the move of our headquarters, we are very pleased that CAPTIS is a part of Utah's thriving life sciences community!

Kristian C. Campbell, kristian@captis.com, (424) 283-1017

www.captis.com

A Proud Member of



BIOUTAH



biohive



67th President of the UN General Assembly, H. E. Vuk Jeremic

Kristian and the CAPTIS team possess deep networks and global connections for executive search and board services within the US and internationally. They expertly evaluate executives for precision placements in critical positions, always acting with integrity and the highest ethical standards.



**Intermountain
Healthcare**

Healing for life®

INNOVATING BEYOND

**HEALTHCARE
DELIVERY +**

5+

Ways Intermountain Healthcare
is Innovating Beyond Healthcare
Delivery to Reduce Costs and
Improve the Health of Patients
and Communities

In the nearly 50 years since the Church of Jesus Christ of Latter-day Saints gifted its hospital system to the communities it served, Intermountain Healthcare (Intermountain) has built upon a long history of providing high-quality, low-cost care, and a rich legacy of using computers and healthcare innovation to improve patient outcomes. Intermountain has become a nationally recognized leader in each of those areas.

Nationally, healthcare spending accounts for nearly 20% of the U.S. economy and the rising cost of healthcare remains unsustainable. To address this affordability crisis and some of the pain points in U.S. healthcare, Intermountain is working to fundamentally shift how healthcare is delivered by focusing on prevention and population health and developing future-focused clinical and business models, driving life sciences, medical and technological advancements, enhancing the patient experience, and increasing access to care by providing it in new, innovative ways.

“Intermountain is committed to being a model health system, which in essence means we must be on the leading edge,” said former Utah governor and new Intermountain Board Chair Mike Leavitt. “We have a responsibility and commitment to the communities we serve to bring them the most affordable, high quality, and accessible health services, and technological and medical advancements.”

“We do this through innovation – our own and with community partners. If we can do this as one of the nation’s largest non-profit, integrated health systems

in some of the fastest growing areas of the country, and with patient experience at the forefront, then our physical and technological reach will expand and we will become the model to follow," he added.

1 _ One way Intermountain is fostering an innovative culture is through its Intermountain Foundry program, which is a more encouraging version of the entrepreneurial television show Shark Tank, but for the company's caregivers (employees). Launched in 2017 in partnership with Healthbox, the Foundry helps would-be inventors turn their ideas for solving problems into viable business solutions that can be used and scaled within Intermountain and more broadly across the industry. Many of these innovations fall squarely in the realm of life sciences innovations.


2 _ The Intermountain Ventures Fund, the strategic investment vehicle of Intermountain, supports internal and external innovation with its purpose to source, evaluate and invest in innovative companies that demonstrate impact in improving healthcare quality and lowering costs, which align with Intermountain's mission and represent a high-return, high-growth opportunity. The fund supports proof-of-concept pilots, spinouts, strategic investments and new commercial business partnerships.

Intermountain has also launched initiatives, studies and nonprofits that aim to solve long-standing challenges that have plagued health systems. The following three examples are illustrative of these efforts.

3 _ Civica Rx (Civica) is a not-for-profit pharmaceutical manufacturer formed by philanthropies and health systems comprised of 1,500 hospitals, including Intermountain. Civica aims to address the issue of affordable pharmaceuticals, even for generic medications. Civica has ensured stable and predictable supplies – and fair pricing – of nearly 60 different generic medications to date. Most recently, Civica announced plans to develop, manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin beginning in 2024. Civica represents a real market response to the demand for affordable pharmaceuticals instead of government imposed price controls.

4 _ Intermountain's Precision Genomics (IPG) division in St. George is leading the way in precision medicine, which is the future of healthcare. Recognized as one of the top 10 emerging technologies to watch, IPG is changing how healthcare is delivered, including how cancers are treated by using TheraMap, a state-of-the-art test for patients with advanced-stage cancer.

TheraMap analyzes and interprets what changes or gene mutations are present in a patient's tumor DNA. It detects important mutation types across more than 500 genes relevant to cancer treatment, relevant gene fusion





events – including NTRK fusions, and important microsatellite instability (MSI) and tumor mutational burden (TMB) biomarkers. TheraMap results help personalize treatment for each patient. TheraMap’s methods provide significantly better results for patients at lower overall healthcare costs than traditional diagnostic tests and treatment.


Other innovative efforts include the HerediGene: Population Study, a large research study that looks at genetic risk for various diseases. Intermountain has already enrolled 125,000 participants with a goal of enrolling 500,000. Researchers are using the study’s data to learn new things about how genetics influence different health conditions: “We’ve already made three extraordinary discoveries, including discovering a genetic link to vertigo,” said HerediGene’s founder Lincoln Nadauld, M.D., Ph.D. “All of them have an enormous impact on how we care for patients.”

5 – Intermountain is an active partner in Clinical Lab 2.0, a Project Santa Fe Foundation Initiative. Clinical Lab 2.0 seeks to use lab data to keep people healthy. Intermountain is using lab data to proactively identify people at risk for diabetes and kidney disease.

Patients with prediabetes are connected with diabetes prevention resources via established pathways. Of the patients who eventually develop Type 2 diabetes, the percentage who progress from prediabetes to Type 2 within three years has decreased from 51.8 percent in 2018 to 7.2 percent in 2021. The impact is substantial,

since 40,000 patients in Utah have lab-confirmed prediabetes. The annual cost savings per patient is approximately \$3,500.

Intermountain uses lab data to identify patients with chronic kidney disease who haven’t received a referral to a kidney specialist. Without timely diagnostic tools, these patients often end up in the emergency room on dialysis, as few know they have the illness. Instead, this approach helps identify patients not yet receiving care, schedule an appointment with a nephrologist. Intermountain is squarely in the diagnostics business with this initiative.

Each of these endeavors shows Intermountain is committed to its mission: “Helping people live the healthiest lives possible.” This means being willing to support and fund new ventures and initiatives by investing in life sciences, digital health and innovative healthcare solutions like these. Without the courage to disrupt a healthcare industry in need of change, achieving this mission would not be possible. 



en-gage /in'gāj/

adjective

morally committed to a particular aim or cause

EXPERTS IN LIFE SCIENCES

Engage Contracting is a commercial construction management firm who specializes in bringing the right construction delivery method to our customers. From Preconstruction Planning, Design-Build, to Construction Management, Engage Contracting is there to ensure the construction process is as seamless as possible. Our goal is to support the Life Science industry by providing specialized construction management services for regulated environments, warehouse and packaging, research and development, healthcare, operating rooms, as well as office and company amenities.

TURNKEY CONSTRUCTION PARTNER

- **Preconstruction Planning:** At Engage Contracting we are ready to provide answers to questions you may have regarding your project. Whether you are struggling to identify budget needs or need to hire an architect or engineer, let us partner with you and provide a strategic perspective that will get your project started on the right foot.
- **Design-Build:** Engage Contracting is well acquainted with some of the best architects and engineers on the Wasatch Front and Intermountain region. With our strong design-build history and relationships, we will help you select a team that is most qualified for your project needs and has the specific expertise to ensure you get the best design for your project.
- **Construction Management:** Engage Contracting is dedicated to ensuring your project is an absolute success. As a team, it is our goal to ensure that all parties share in that success. We welcome our client's toughest challenges and excel at executing the construction phase with extreme attention to detail. We have spent decades building relationships with local subcontractors who are highly qualified and thrive on ensuring we build the best project with the most value to our client.



Innovation starts with inspiration. And we're inspired.

By creating a community
unified around a single passion:
To help patients live longer,
healthier and more productive lives.

By working with clinicians to solve
unmet needs and make meaningful
differences across the healthcare system.

By evolving a portfolio of breakthrough
technologies with a patients-first mindset.

Edwards Lifesciences.
From inspiration to realization.



Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2019 Edwards Lifesciences Corporation. All rights reserved. PP--US-1611 v3.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com



Edwards

CACHE VALLEY

Cache County boasts the highest concentration of life sciences jobs in Utah. Is that surprising? It shouldn't be. What started with Dr. Rex Spendlove's HyClone™ Labs and Wayne Barlow's Wescor, combined with the resources of Utah State University, have now evolved into an array of innovative companies in this northern valley, creating new medical technologies and employing thousands.

CYTIVA

In the 1960's, Dr. Rex Spendlove launched HyClone™ Labs in Logan, Utah, which manufactured cell culture media and serum along with other related products. Through multiple ownership changes, Cytiva has emerged as the owner of that original technology and continues today manufacturing cell culture media and serum. Part of the Danaher Life Sciences platform, Cytiva has global reach, providing technologies and services that accelerate the delivery of therapeutics for patients with conditions such as Alzheimer's, COVID-19, the flu and cancers.



"Cache Valley is great for Cytiva," said Justin Meehan, plant manager for Cytiva's Logan site. "Here, we have opportunities to grow and attract a pipeline of talent from multiple sources, such as Utah State University.

The investment to date shows the level of confidence in the Utah team."

The company plans to add about 270,000 square feet to its Logan facility, doubling production. This expansion, combined with the recent acquisition of Utah-based Intermountain Life Sciences, a manufacturer of liquid cell culture media and buffers, solidifies Cytiva's commitment to the Cache Valley community and Utah's life sciences industry.

ELITTECHGROUP BIOMEDICAL SYSTEMS

ELITechGroup Biomedical Systems has been in operation for over 50 years and distributes to over 100 countries. With a significant footprint in Logan, Utah, the company is proud to be the world leader in Aerospray® staining technology and Cyto centrifugation used in hematology, gram, tuberculosis, and cytology staining.



In addition, ELITechGroup Biomedical Systems is the gold standard in the U.S. and across the globe for conducting diagnostic tests to determine cystic fibrosis and provide specialized Erythrocyte

Sedimentation Rate (ESR) to assess and analyze blood samples from patients for a variety of hematology disorders and inflammation. They also provide vapor pressure and freezing point osmometers for clinical, research and pharmaceutical labs.

Offering the world's most reliable solutions in performance and reliability, ELITechGroup Biomedical Systems' mission is to improve patient care by empowering labs to do more in less time, with accuracy, to enable rapid and accurate treatment for patients.

SCYTEK LABORATORIES

ScyTek Laboratories, founded in 1991, is a world-class manufacturing company producing reagents for the life sciences. From its early days of producing ELISA reagents for the OEM market, ScyTek Laboratories has expanded its production capabilities to include Immunohistochemistry Reagents, Special Stains, Routine Stains, Buffers, Mounting Media, Fixatives, Diluents and a wide variety of custom reagents. The customer focus is on manufacturing products primarily for the OEM/Private Label markets.

Whether "off the shelf" or "custom production" ScyTek Laboratories delivers the highest quality product, delivered at exactly the right time. The company has the capability to produce most any liquid for the lab and can customize packaging to meet nearly any requirement.

ScyTek Laboratories recently added a new 8,000 square foot modernized facility in Logan, Utah, a place ScyTek Laboratories is proud to call home.



A LIFE SCIENCES STAND OUT

Stringent raw material screening processes ensure that all manufactured products are of the highest quality. As a primary manufacturer, ScyTek Laboratories has grown steadily year over year by identifying areas that can be improved through the implementation of Kaizen and other manufacturing management techniques. Aggressive pricing through vigilant cost containment and continuous improvements in efficiency have helped to foster strong customer bonds.



ScyTek Laboratories' new 8,000 square-foot facility.

THERMO FISHER SCIENTIFIC

This past April, Logan-based Thermo Fisher Scientific hosted a grand opening ceremony and ribbon-cutting event at its new facility in Ogden, Utah.

The \$44 million, 55,000-square-foot facility is manufacturing highly customizable bioprocess container (BPC) systems. These BPCs are used to advance the production of life-saving biologics, vaccines and cell and gene therapies. The new site magnifies Thermo Fisher Scientific's current operations in Utah, which include complementary sites in Logan and South Jordan.

"The Ogden facility further strengthens our global manufacturing network," said Mitch Kennedy, president, single-use technologies of Thermo Fisher Scientific. "This new facility expands our presence in Utah. Locating here gives us the ability to work closely with our Logan site."



Thermo Fisher Scientific Ribbon Cutting on April 20, 2022 in Ogden, UT.

With more than 300 employees in Ogden, and more than 2,000 employees across its three sites, Thermo Fisher Scientific is an integral part of Utah's burgeoning biotech economy, and a sign that the future of healthcare is alive and well in Cache Valley.

FRONTIER SPECIALTY CHEMICALS

Frontier Specialty Chemicals is a privately held corporation established in 1975 and headquartered in Logan, Utah, specializing in the advanced synthesis of porphyrins, organoborons for transition metal coupling, synthesis building blocks, and custom and specialty chemistries for the research sciences. All this technical complexity, however, can be summed up in the company's mission to pursue innovative chemistry solutions to improve the human condition.



Frontier Specialty Chemicals provides unique specialty chemicals used in many industries, including organic synthesis services to the research community and pharmaceutical industry. The company has been

involved in the development of treatments for acute kidney injury and cancer.

The company provides a key ingredient used in the newest generation of long-term continuous glucose monitors. They're also providing a key material for a novel vaccine technology currently in clinical trials. For many years, Frontier Specialty Chemicals has been developing a series of novel chemicals for removal of harmful blue light in optical applications to prevent macular degeneration. The company collaborates with

chemists and scientists worldwide solving a variety of chemical and medical problems, all while conducting its business with integrity and fostering a safe, inclusive and respectful workplace.


QUANSYS BIOSCIENCES

Quansys Biosciences was founded by Dr. Rex Spendlove to develop assays that accelerate research in the diagnosis and treatment of diseases. What his team created became the Q-Plex Multiplex ELISA and the Q-View Imaging System.



Quansys Biosciences' development principles keep the technology as accessible as possible without compromising sensitivity or accuracy. This robust and reliable technology platform has garnered

partnerships with industry leaders, which in turn benefits research and diagnostics throughout the world in the fields of cancer, infectious diseases, cardiovascular health, malaria and nutrient deficiency. Combined with world-class customer service, Quansys Biosciences has earned global appeal and now has growing customer bases in Africa, the Middle East and Asia.

Regarding its Cache Valley beginning, Quansys Biosciences' CEO, Adam Brown said, "I am honored to be a part of a Utah based company that is able to have a global impact on health. Quansys Biosciences hopes to continue to grow, sticking to these ideals of forming lasting partnerships and leading in the campaign for a disease-free world." 



Safeguarding Global Health[®]

- with every test we complete.

We are a leading global provider of mission-critical lab testing and advisory services for the healthcare industry.

We perform over 800 microbiological and analytical laboratory tests for the medical device and pharmaceutical industries.

**For your product testing,
contact our team of
experts today!**

Sales US +1 801-290-7502 | Sales@NelsonLabs.com



Come make a difference with us.

Alpa Patel 2003—Lab Analyst, Today—Director of Scientific Improvement

"My passion for science began in middle school. Today, this passion helps save lives!"

Join our team!

Learn more at www.nelsonlabs.com/careers

www.NelsonLabs.com

 **Nelson Labs[®]**
A Sotera Health company

BIG IDEAS



Scrappy startups aren't the only ones in the innovation business. Just ask these leading Utah life sciences companies that continue to bring new big ideas to the healthcare market. For them, innovation is the name of the game no matter how much they grow, build out and prosper. These companies constantly push the boundaries of science and technology to improve how we diagnose and treat disease, perform procedures and ultimately spawn life-changing healthcare solutions.



Decades ago in Utah, Becton, Dickinson and Company (BD) and C. R. Bard, Inc., began their journey to reshape patients' lives by reinventing vascular access treatment. In 2017, these two companies joined forces to become the BD Vascular Access Device business and one of Utah's largest employers. Today, BD is the global leader in vascular access, celebrates 125 years in business, is stronger than ever and poised to reimagine healthcare yet again.



Photo courtesy of Joan Ford Photography

Innovation is at the heart of BD. As a global leader in vascular access, the company has the opportunity and responsibility to drive more value out of its 800 million annual patient interactions.

Applying breakthroughs in medtech like infection management, creatively rethinking clinical procedures, using new tools and leveraging digital technologies, BD is on a journey to transform healthcare.

BD is committed to creating better outcomes for patients and providers everywhere. Every day, its teams work tirelessly to reshape the future of healthcare through transformative solutions.



A family-owned company, bioMérieux has become a pioneering leader in the field of in vitro diagnostics. With a \$90 million North American headquarters in Salt Lake City – the bioscience firm employs nearly 3,000 Utahns with an unrelenting commitment to combat infectious diseases worldwide.



Innovation is a core pillar of bioMérieux’s growth strategy. For nearly 60 years, the company has been innovating to drive progress in pathogen detection and identification.



bioMérieux's New Utah Headquarters

“Infectious diseases are one of the major threats to humankind,” said Andrew Hemmert, Ph.D., senior vice president, Molecular BIOFIRE® R&D and Programs. “The risk of finding ourselves unarmed to face ultra-resistant bacteria is real. Diagnostics is a game-changer in this fight.”

As an example, in May 2022, bioMérieux received De Novo authorization from the FDA for its Salt Lake City-developed BIOFIRE® Joint Infection Panel. This panel tests for 31 pathogens implicated in most acute joint infections and also optimizes antibiotic therapy and stewardship.

“This authorization reflects our continued cutting-edge leadership in molecular syndromic testing,” added Hemmert.



Co-Dx™ is a molecular diagnostics provider with unique, patented technology which enables the design of high-performing, cost-effective PCR tests with application for infectious disease, liquid biopsy, SNP detection, vector surveillance and agricultural genetics testing.



Co-Dx PCR Home Testing Platform

Co-Dx was founded in 2013 on the principle of making PCR diagnostics ubiquitously available even in areas of the world where infrastructure and pricing make PCR unfeasible. Recently, the company announced the development of the Co-Dx PCR Home* testing platform, designed to make it possible for PCR tests to be done anywhere, in real time, all while enabling global surveillance.

Following a CE marking and an Emergency Use Authorization from the FDA, more than 31 million units of the Co-Dx PCR assay for COVID-19 have been purchased for use in high complexity labs in more than 50 countries worldwide and across the U.S.

**This product is subject to FDA review and is not available for sale.*



Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address challenging healthcare conditions and significant unmet clinical needs - working to improve patient outcomes and enhance lives.

The company established its Utah roots in 1997 with the acquisition of Research Medical Inc., based in Midvale, Utah. In 2010, Edwards Lifesciences began manufacturing cardiac surgery systems products and accessories for its transcatheter heart valve systems in Draper, and transferred all existing operations and

approximately 250 employees from its Midvale facility to Draper, Utah. Currently, there are approximately 1,000 employees in Draper.



Employees of Edwards Lifesciences in Draper

Edwards Lifesciences' long-term growth is fueled by innovation. Last year, the company invested 17 percent of sales in research and development (R&D), and product growth in recent years is directly related to the outputs of this R&D. Edwards Lifesciences has been proud to introduce several innovative products that have enabled more patients to benefit from the company's life-saving technologies than ever before.



Innovation is the hallmark of Merit Medical. The company's SCOUT® Radar Localization System, first introduced into clinical use in 2015, helps reduce the burden breast cancer places on patients and their loved ones.

Successful breast conservation surgery minimizes damage to healthy tissue while completely removing cancer cells. Surgeons must precisely locate the tissue to be removed. Traditionally, following a biopsy procedure, if cancer cells were detected, prior to surgery, a radiologist used imaging technology to insert thin wires into tissue that was to be removed. Wires protruded through the skin showing the surgeon where to operate, which was uncomfortable for patients and called for multiple procedures.

Merit Medical's technology innovates breast conservation surgery, helping surgeons to precisely target tumors, minimizing removal of healthy breast tissue. A small radiopaque marker, the size of a grain of rice, is implanted beneath the skin to identify tissue for removal prior to surgery. A new MRI compatible SCOUT system allows markers to be implanted at the time of biopsy so patients can avoid a return visit.



Merit Medical's 2019 Console with Access Guide

During surgery, using a small hand-held wand, a surgeon locates the marker to precisely excise the right tissue. The SCOUT markers provide a more comfortable, streamlined patient experience. Today, SCOUT is the most frequently used localization system.



Today, as one of the world's leading medtech companies, with a presence in over 70 countries around the globe, Stryker continues to pursue its mission of making healthcare better through its end-to-end approach to stroke care.


The company has a rich history of advancing the neurovascular space and is proud to have brought forward many leading innovations that have become trusted partners for customers such as the Target Detachable Coil, rpass Flow Diverter, Neuroform Atlas Stent and Synchro Guidewire. Today, in this golden era of neurovascular innovation, Stryker is delivering leading technological advancements through its robust pipeline of next generation hemorrhagic, acute ischemic stroke

and access devices. The foundation of its future stroke technologies is powered by clinical evidence, with the goal of helping deliver better stroke treatment to the patients their customers serve. Currently, active in over 30 ongoing clinical studies like the ASSIST Registry and IMPACT EU studies, Stryker strives to drive meaningful clinical research that increases medical knowledge like the landmark results of our DAWN Trial, that helped change stroke care guidelines worldwide.



Stryker's Surpass Evolve Flow Diverter is used to treat brain aneurysms.

The company understands that improving stroke care starts before - and goes beyond- the point of treatment. The company is dedicated to helping physicians continuously improve their skills and stroke practice through our SKILL Medical Education program. Stryker is proud to bring forward revolutionary advancements in the medical-education space through its SKILL Assist Remote Medical Education platform, enabling collaboration between physicians during a procedure from anywhere in the world. They're also helping address the challenges of stroke management with its StrokEnomics program. Supported by the highest levels of clinical and economic data, StrokEnomics can help hospitals form strategies to navigate funding barriers and help increase patient access to the best treatment modalities and quality of care.

Stryker is driven by a culture and mission that impacts patient lives—it's at the heart of everything they do. The company remains fully dedicated to its partnerships with its customers, working tirelessly to bring forward the latest advancements in technology, clinical research, and a full-service portfolio. 



FORGING

A CANCER

REVOLUTION



While tremendous progress has been made in the fight against cancer, still one in two people will be diagnosed with cancer during their lifetime and one in five will die. These visionary Utah companies are working overtime to change that. Focused on revolutionizing how we detect cancer and personalize treatments, these companies are heralding a new era of life-saving technologies to one day end the pain and suffering that this disease inflicts on so many.

Early detection saves lives. That’s why IONIQ Sciences is decoding the science of the body’s earliest response to the presence of cancer by measuring the electrical properties of the human body—it’s called bioimpedance.



The LUNA3™ from IONIQ Sciences.

“The body’s electrical properties change very early on in the presence of cancer,” explained Jared Bauer, CEO of IONIQ Sciences. “Our non-invasive bioimpedance technology can detect these changes in the disease’s earliest, most-treatable stages, when it matters most. When it comes to early detection, our test dramatically outperforms well-known, blood-based tests or liquid biopsies by a margin of three to five times. And our test can reduce false positives by 86 percent versus today’s imaging standard of care.”

The company has already completed seven studies and trials at 25 sites across three continents with 1,400 subjects on its way to create a simple 20-minute test with no needles, no radiation and no surgery. Based on the life-enhancing potential demonstrated by IONIQ’s clinical evidence, the FDA designated their lung cancer test a “breakthrough device,” and is currently evaluating their de novo application for marketing clearance.

Currently, the test development pipeline includes lung, breast and GI cancers. IONIQ recently unveiled their next-generation platform called LUNA3. It is designed to move early cancer detection out of doctor’s offices and into pharmacies, and ultimately into consumers’ homes.

Andrea Mazzocchi and Katie-Rose Skelly knew Utah was a nourishing environment when founding Known Medicine. Mazzocchi, who had spent a decade designing tissue-relevant biomaterials, and Skelly, an artificial intelligence (AI)-for-drug-discovery data scientist, were drawn to the growing biotech scene in Salt Lake City.

Known Medicine’s mission is simple—to improve cancer patients’ lives. To do this, they are combining patient-specific 3D cell culture and AI to translate cancer therapies to clinical success. From scientists to software engineers, their team of multidisciplinary technical experts collaborate in designing the dataset and deciphering results. They also recognize every cancer is unique, and have partnered with leading research institutions nationwide to understand patient response.



Katie-Rose Skelly and Andrea Mazzocchi of Known Medicine

“Known Medicine aims to address the large failure rate of oncology drugs going from Phase 1 clinical trials to on-market”, said CEO and co-founder, Andrea Mazzocchi. Adding -omics data for each patient, Known Medicine can determine how individual patients will respond to new drug treatments and why. Revolutionary!



Myriad genetics

The mission of Myriad Genetics, a global leader in genetic testing and precision medicine, is to advance health and well-being for all. The company provides healthcare providers with data-driven, medical information for patients diagnosed with cancer or individuals who may have an inherited risk of developing cancer.



Dr. Slavig of Myriad Genetics

Myriad's MyRisk™ Hereditary Cancer Test is a multi-gene panel that helps determine a patient's hereditary cancer risk associated with 11 primary cancer sites. Additionally, Precise™ Oncology Solutions offers a comprehensive suite of tests for patients with solid tumors, including


germline testing, tumor profiling and companion diagnostics. The combination of these tests makes it easier to personalize treatment and/or match patients to specific clinical trials.

As part of its expanding oncology portfolio, Myriad Genetics is adding a new liquid biopsy therapy selection test, in partnership with Intermountain Precision Genomics, which is expected to be available in 2023. The company is also developing its own Minimal Residual Disease (MRD) test in-house using its existing core competencies.



Peel Therapeutics is unlocking evolutionary biology to help patients with cancer and inflammatory diseases. Peel Therapeutics began with the discovery at Huntsman Cancer Institute that elephants contain extra cancer fighting proteins that work better than human proteins

at preventing cancer ("Peel" is the Hebrew word for elephant). The company quickly recognized the power of using evolution's solutions and now has several nature-based medicines in the pipeline.



Peel Therapeutics' Team

Peel Therapeutics seeks distinct molecules in nature that exceed what is considered biologically possible and then engineers them to treat devastating conditions. Its lead compound, originating from an ancient tree used for more than 2,000 years in traditional Chinese medicine, has been successfully modified to avoid chemotherapy resistance. Patients have begun to enroll in a clinical trial to test the safety of this new medicine.

"Our Peel scientists in Utah and Israel work around the clock to turn these evolutionary wonders into life-changing medicines for patients with unmet clinical needs," said Joshua Schiffman, M.D., Peel co-founder/CEO.


Sumitomo Pharma

Sumitomo Pharma Oncology

Sumitomo Pharma Oncology, Inc. (SMP Oncology) is a clinical-stage pharmaceutical company focused on discovery, development and commercialization of drugs for emerging and unique targets and pathways which have the potential to change the paradigm of oncology treatment and management.

Steve Warner, senior vice president and head of U.S. research at SMP Oncology, details the company's overall strategy and goals further. "We are committed to identifying and advancing novel therapeutics that may

make a meaningful difference in the lives of patients with cancer," he said. "The company's focus is not singular, rather it is spread across a diverse pipeline and spans a spectrum of various mechanisms with the goal of addressing unmet needs in oncology."

SMP Oncology is relentlessly fueled by scientific persistence and a commitment to discovery. Recently, SMP Oncology announced Orphan Drug Designation approval for three assets, TP-3654, DSP-5336 and DSP-0390, and now has more than five assets being investigated in various phases of clinical studies. 

REVOLUTION

BIOHIVE SUMMIT SALT PALACE . NOV.10.2022

PRESENTED BY



biohive



BIOUTAH

BIOUTAH.ORG

ADVOCACY



Pictured left to right: Sen. Ann Millner, Rep. Steven Eliason, Rep. Jen Dailey-Provost, Sen. Luz Escamilla

LEGISLATORS LEAN IN ON LIFE SCIENCES

Utah legislators are finding unique ways to connect with the state's life sciences community. Last year, a legislative caucus was formed and the Governor's Office of Economic Opportunity has long hosted an annual life sciences industry day at the Capitol. Both help legislators learn more about this high-growth, innovative sector and how policy decisions can impact its future. Here's a snapshot.

THE LAUNCH OF A LIFE SCIENCES CAUCUS

In 2021, Senators Ann Millner and Luz Escamilla along with Representatives Steven Eliason and Jen Dailey-Provost founded the Utah Life Sciences Innovation Caucus (ULSIC).

"I'm excited about bringing together my colleagues to help support the industry's expansion and the innovation that will drive solutions to some of our most pressing healthcare challenges," said Senator Millner.

The purpose of the ULSIC is to raise the visibility of this sector as well as educate lawmakers about the industry's role in the state's economy and what it takes to spur medical breakthroughs.

"Utah has a proud tradition of medical discoveries," said Senator Escamilla. "We want to ensure this pioneering spirit continues to thrive."




LIFE SCIENCES DAY ON CAPITOL HILL

Once a year, Utah's Capitol goes from lawmaking to laboratory as dozens of the state's life sciences companies showcase their medical innovations.

This year, the event was held February 16, featuring 24 medical technology, diagnostic and biotechnology companies, from Logan to St. George. There were startups finding new ways to fight cancer and test for disease, as well as large established manufacturers advancing stroke care and replacement heart valves. They filled the Capitol rotunda.

Lt. Governor Deidre Henderson and more than 20 percent of the legislature visited the company exhibits and talked with industry leaders.

"This gathering allows legislators to talk one-on-one with innovators and see first-hand the life-changing technologies being developed right here in the state of Utah," said Kelvyn Cullimore, BioUtah President and CEO. 

**At Sumitomo Pharma Oncology,
we believe that purposeful science
holds the potential to improve the
lives of people with cancer.**

Learn more at oncology.sumitomo-pharma.com/about

 **Sumitomo Pharma**

Sumitomo Pharma Oncology

Sumitomo Pharma Oncology is a registered trademark of Sumitomo Pharma Co., Ltd.
©2022 Sumitomo Pharma Oncology, Inc. All rights reserved. PM-NPS-0141



As biopharmaceutical researchers
keep searching for breakthrough cures
they don't have to look far for inspiration.

In this new era of medicine, where breakthroughs
are transforming prevention and treatment options,
PhRMA is committed to fixing America's health
care system the right way.

PhRMA
RESEARCH • PROGRESS • HOPE

www.PhrMA.org/BetterWay